DE69628333D1 - Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren - Google Patents

Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren

Info

Publication number
DE69628333D1
DE69628333D1 DE69628333T DE69628333T DE69628333D1 DE 69628333 D1 DE69628333 D1 DE 69628333D1 DE 69628333 T DE69628333 T DE 69628333T DE 69628333 T DE69628333 T DE 69628333T DE 69628333 D1 DE69628333 D1 DE 69628333D1
Authority
DE
Germany
Prior art keywords
disorders
compounds
disease
acetylcholine receptors
dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69628333T
Other languages
English (en)
Other versions
DE69628333T2 (de
Inventor
Michel Vernier
A Mcdonald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE69628333D1 publication Critical patent/DE69628333D1/de
Application granted granted Critical
Publication of DE69628333T2 publication Critical patent/DE69628333T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69628333T 1995-11-17 1996-11-14 Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren Expired - Lifetime DE69628333T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55982195A 1995-11-17 1995-11-17
US559821 1995-11-17
PCT/US1996/018569 WO1997019059A1 (en) 1995-11-17 1996-11-14 Novel substituted aryl compounds useful as modulators of acetylcholine receptors

Publications (2)

Publication Number Publication Date
DE69628333D1 true DE69628333D1 (de) 2003-06-26
DE69628333T2 DE69628333T2 (de) 2004-04-08

Family

ID=24235168

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69628333T Expired - Lifetime DE69628333T2 (de) 1995-11-17 1996-11-14 Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren

Country Status (8)

Country Link
EP (1) EP0874818B1 (de)
JP (1) JP3969741B2 (de)
AT (1) ATE240942T1 (de)
AU (1) AU717012B2 (de)
CA (1) CA2237752C (de)
DE (1) DE69628333T2 (de)
ES (1) ES2197255T3 (de)
WO (1) WO1997019059A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
BR9907170A (pt) 1998-04-02 2000-12-26 Reynolds Tobacco Co R Composições farmacêuticas e métodos para uso
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6262124B1 (en) 1998-10-22 2001-07-17 Gary Maurice Dull Pharmaceutical compositions and methods for use
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
CA2386049A1 (en) 1999-10-15 2001-04-26 Daniel S. Gardner Bicyclic and tricyclic amines as modulators of chemokine receptor activity
US6784200B2 (en) 2000-10-13 2004-08-31 Bristol-Myers Squibb Pharma Company Bicyclic and tricyclic amines as modulators of chemokine receptor activity
EP1467986A1 (de) 2002-01-17 2004-10-20 Eli Lilly And Company Azacyclische verbindungen als modulatoren von acetylcholinrezeptoren
US7148236B2 (en) 2002-01-17 2006-12-12 Merck & Co., Inc. Modulators of acetylcholine receptors
KR20050114641A (ko) 2003-03-07 2005-12-06 아스텔라스세이야쿠 가부시키가이샤 2,6-이치환된 스티릴을 갖는 질소 함유 헤테로환 유도체
CA2564994A1 (en) 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
EP1802258A4 (de) 2004-09-13 2015-09-23 Chrono Therapeutics Inc Biosynchrone transdermale arzneiabgabe
CN101772346B (zh) 2007-04-02 2014-05-07 帕金森氏病研究院 用于降低治疗副作用的方法和组合物
JP6082250B2 (ja) 2010-02-09 2017-02-15 ザ・ジョンズ・ホプキンス・ユニバーシティー 認知機能を改善するための方法および組成物
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (de) 2013-03-15 2021-05-05 Agenebio, Inc. Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
US11285306B2 (en) 2017-01-06 2022-03-29 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
CN108383775A (zh) * 2018-03-07 2018-08-10 泰州医药城国科化物生物医药科技有限公司 二芳基乙烯基环胺衍生物及其制备方法
EP3801732A4 (de) 2018-05-29 2022-04-27 Morningside Venture Investments Limited Verfahren und systeme zur wirkstofffreisetzung
WO2020077024A1 (en) * 2018-10-10 2020-04-16 Albert Einstein College Of Medicine Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators
WO2022156784A1 (zh) * 2021-01-22 2022-07-28 武汉人福创新药物研发中心有限公司 杂环类化合物的制备方法及其中间体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721783A (en) * 1986-01-09 1988-01-26 United Pharmaceuticals, Inc. Anti-spasmodic agents having a heterocyclic ring
WO1994007489A1 (en) * 1992-10-02 1994-04-14 The Salk Institute For Biological Studies Non-competitive inhibitors of neuronal nicotinic acetylcholine receptors
US5472958A (en) * 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
US5567710A (en) * 1994-10-13 1996-10-22 Sibia Neurosciences, Inc. Polycyclic fused ring modulators of acetylcholine receptors

Also Published As

Publication number Publication date
EP0874818B1 (de) 2003-05-21
WO1997019059A1 (en) 1997-05-29
JP2000501080A (ja) 2000-02-02
JP3969741B2 (ja) 2007-09-05
CA2237752C (en) 2006-05-16
ATE240942T1 (de) 2003-06-15
DE69628333T2 (de) 2004-04-08
AU1078297A (en) 1997-06-11
AU717012B2 (en) 2000-03-16
EP0874818A1 (de) 1998-11-04
CA2237752A1 (en) 1997-05-29
ES2197255T3 (es) 2004-01-01

Similar Documents

Publication Publication Date Title
DE69628333D1 (de) Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren
ATE271040T1 (de) Substituierte pyridinderivate, deren herstellung und deren verwendung als modulatoren von acetylcholin-rezeptoren
ATE248160T1 (de) Pyridin acetylcholin-rezeptor-modulatoren
TR199700644T1 (xx) Serotonin-ili�kili sistemler �zerinde etkiye sahip bile�ikler.
WO2000070049A3 (en) Extracellular signaling molecules
ATE175695T1 (de) Stickstoffhaltige polymere als elektrolumineszenzmaterialien
MY138267A (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
IL124728A0 (en) Diagnosis and treatment of aur-1 and/or aur-2 related disorders
PT1003863E (pt) Receptor-11 de citoquinas de mamifero
HU9400728D0 (en) Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
DE69528823D1 (en) Morpholinwirkstoffvorläufer als tachykininreceptorantagonisten
ATE361364T1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
BG106508A (en) Alkylene diamine-substituted heterocycles
AU6877694A (en) Tricyclic benzazepine vasopressin antagonists
ATE321855T1 (de) Tumor-nekrose-faktor rezeptor 5
WO2001055163A8 (en) Nucleic acids, proteins, and antibodies
Oki et al. Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice
PE20010516A1 (es) Peptidos ciclicos con afinidad mejorada por los receptores de somatostatina
ATE245632T1 (de) Benzodiazepin derivate verwendbar als cck- rezeptoren antagonisten
PT1137413E (pt) Antagonistas nao-peptidicos do receptor de glp-1 e metodos de utilizacao
DE69610628D1 (de) N-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-3-amide
McDonald et al. 2, 7-Dioxo-2, 3, 4, 5, 6, 7-hexahydro-1 H-benzo [h][1, 4] diazonine as a New Template for the Design of CCK2 Receptor Antagonists
FI964045A0 (fi) CCK:ta tai gastriinia säätelevä 5-heterosykli-1,5-bentsodiatsepiinejä
ES2180575T3 (es) Pirido(2,3-b)(1,4)benzodiazepinonas como ligando de receptor m2 para el tratamiento de trastornos neurologicos.
DE60007841D1 (de) Neue azabicyclo derivate und ihre verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO., INC., RAHWAY, N.J., US